Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Public ClinicalTrials.gov record NCT06106672. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18-75 With Generalized Myasthenia Gravis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Study identification
- NCT ID
- NCT06106672
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 54 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2024 (Actual)
- Primary completion
- Jun 2026 (Estimated)
- Completion
- Aug 2026 (Estimated)
- Last update posted
- Jun 9, 2026
2024 – 2026
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Barrow Neurological Institute | Phoenix | Arizona | 85013 | — |
| Infusion for Health | Brea | California | 92835 | — |
| University of California, Irvine | Orange | California | 92868 | — |
| University of California, Davis | Sacramento | California | 95817 | — |
| Yale University | New Haven | Connecticut | 06516 | — |
| Atlantis Research | Miami | Florida | 33173 | — |
| Quantix Research, LLC | Miami | Florida | 33173 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| Insight Hospital and Medical Center | Chicago | Illinois | 60608 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| Insight Research Institute, Dearborn | Dearborn | Michigan | 48126 | — |
| University of Missouri, NextGen Precision Health | Columbia | Missouri | 65211 | — |
| Ohio State University Wexner Medical Center | Colombus | Ohio | 43221 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Nerve and Muscle Center of Texas | Houston | Texas | 77030 | — |
| Prolato Clinical Research Center | Houston | Texas | 77054 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06106672, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06106672 live on ClinicalTrials.gov.